Olivieri Oliviero, Castagna Annalisa, Guarini Patrizia, Chiecchi Laura, Sabaini Gherardo, Pizzolo Francesca, Corrocher Roberto, Righetti Pier Giorgio
Department of Clinical and Experimental Medicine, University of Verona, Italy.
Hypertension. 2005 Oct;46(4):683-8. doi: 10.1161/01.HYP.0000184108.12155.6b. Epub 2005 Sep 19.
Prostasin is a serine peptidase hypothesized to regulate epithelial sodium channel (ENaC) activity in animals or on in vitro cultured cells. We investigated whether urinary prostasin may be a candidate marker of ENaC activation in humans. We studied 10 healthy volunteers and 8 hypertensive patients with raised aldosterone-to-renin ratio before and after spironolactone or saline/Florinef suppression test, respectively. Four healthy subjects were also studied before and after saline. Urinary prostasin was evaluated by SDS-PAGE, 2D maps, and Western blotting. Every sample of normotensive individuals was compared with the corresponding sample of urine collected after spironolactone or saline; every sample of hypertensive patients was compared with the corresponding sample of urine collected after saline or Florinef. Prostasin was detectable in all subjects regardless of gender, dietary sodium intake, and spironolactone treatment. Spironolactone (100 mg) increased urinary Na+/K+ ratio and decreased urinary prostasin in normotensives in whom the renin/aldosterone axis was activated by a low Na+ intake, but it was ineffective in individuals with high Na+ intake. Saline infusion also reduced prostasin in normotensive subjects. In contrast, prostasin paradoxically increased in urine of patients affected by primary aldosteronism after volume expansion. By 2D immunoblotting, several protein isoforms were observed, some of them being overexpressed after inhibition tests in patients with primary aldosteronism. In addition to a "basal" aliquot of prostasin, constitutively released in human urine regardless of sodium balance and aldosterone activation, there exists a second "aldosterone-responsive" aliquot modulated by Na+ intake and potentially suitable as candidate marker of ENaC activation.
前列腺素酶是一种丝氨酸蛋白酶,据推测可调节动物体内或体外培养细胞中的上皮钠通道(ENaC)活性。我们研究了尿前列腺素酶是否可能是人类ENaC激活的候选标志物。我们分别研究了10名健康志愿者和8名醛固酮与肾素比值升高的高血压患者,在螺内酯或生理盐水/氟氢可的松抑制试验前后的情况。还对4名健康受试者在生理盐水处理前后进行了研究。通过SDS-PAGE、二维图谱和蛋白质印迹法评估尿前列腺素酶。将血压正常个体的每个样本与螺内酯或生理盐水处理后收集的相应尿液样本进行比较;将高血压患者的每个样本与生理盐水或氟氢可的松处理后收集的相应尿液样本进行比较。无论性别、饮食钠摄入量和螺内酯治疗情况如何,所有受试者均可检测到前列腺素酶。螺内酯(100毫克)可增加血压正常者的尿钠/钾比值并降低尿前列腺素酶,这些血压正常者的肾素/醛固酮轴因低钠摄入而被激活,但对高钠摄入个体无效。生理盐水输注也可降低血压正常受试者的前列腺素酶。相比之下,原发性醛固酮增多症患者在容量扩张后尿中前列腺素酶反而增加。通过二维免疫印迹法观察到几种蛋白质异构体,其中一些在原发性醛固酮增多症患者的抑制试验后过度表达。除了在人类尿液中持续释放的“基础”前列腺素酶组分,其释放与钠平衡和醛固酮激活无关外,还存在第二种“醛固酮反应性”组分,其受钠摄入调节,有可能作为ENaC激活的候选标志物。